Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with β-thalassemia intermedia

Blood Cells, Molecules, and Diseases

Volumn 51, Issue 1, 2013, Pages 35-38

  Musallam, Khaled M ^a,b   Cappellini, Maria Domenica ^a   Taher, Ali T ^b,c  

^a UNIVERSITY OF MILAN   (Italy)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c Chronic Care Center Hazmieh   (Lebanon)

Author keywords

Iron overload; Liver iron concentration; Morbidity; Thalassemia intermedia

Indexed keywords

AGE; AGED; ARTICLE; BETA THALASSEMIA; BONE DISEASE; CHILD; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ENDOCRINE DISEASE; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IRON CHELATION; IRON LIVER LEVEL; IRON OVERLOAD; LIVER LEVEL; MORBIDITY; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK REDUCTION; SCHOOL CHILD; THROMBOSIS; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; BETA-THALASSEMIA; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IRON; IRON OVERLOAD; LIVER; MALE; MIDDLE AGED; MORBIDITY; YOUNG ADULT;

EID: 84877128415     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2013.01.015     Document Type: Article

References (15)

1. Musallam K.M., Cappellini M.D., Wood J.C., Taher A.T. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev. 2012, 26(Suppl. 1):S16-S19.
2. Taher A., El Rassi F., Isma'eel H., et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 2008, 93:1584-1586.
3. Musallam K.M., Cappellini M.D., Wood J.C., et al. Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica 2011, 96:1605-1612.
4. Taher A.T., Porter J., Viprakasit V., et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 2012, 120:970-977.
5. St Pierre T.G., Clark P.R., Chua-anusorn W., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005, 105:855-861.
6. Wood J.C., Enriquez C., Ghugre N., et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005, 106:1460-1465.
7. Taher A.T., Musallam K.M., Karimi M., et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010, 115:1886-1892.
8. Kell D.B. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med. Genomics 2009, 2:2.
9. Musallam K.M., Taher A.T., Karimi M., Rachmilewitz E.A. Cerebral infarction in beta-thalassemia intermedia: breaking the silence. Thromb. Res. 2012, 130:695-702.
10. Musallam K.M., Taher A.T. Thrombosis in thalassemia: why are we so concerned?. Hemoglobin 2011, 35:503-510.
11. Musallam K.M., Motta I., Salvatori M., et al. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with beta-thalassemia intermedia. Blood Cells Mol. Dis. 2012, 49:136-139.
12. Belhoul K.M., Bakir M.L., Saned M.S., et al. Serum ferritin levels and endocrinopathy in medically treated patients with beta thalassemia major. Ann. Hematol. 2012, 91:1107-1114.
13. Haidar R., Musallam K.M., Taher A.T. Bone disease and skeletal complications in patients with beta thalassemia major. Bone 2011, 48:425-432.
14. Rivella S. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood Rev. 2012, 26(Suppl. 1):S12-S15.
15. Pootrakul P., Sirankapracha P., Sankote J., et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br. J. Haematol. 2003, 122:305-310.